Verdict TRUE

TRUE — The FDA approved Casgevy in December 2023, and Casgevy is an oral tablet taken every day, But Not Fully

Verified on July 21, 2026

The FDA approved Casgevy in December 2023 for sickle cell disease.

Confidence70%

How strongly independent, cited sources support this verdict.

Claim reviewed

The FDA approved Casgevy in December 2023, and Casgevy is an oral tablet taken every day.

Analysis summary

Direct primary evidence supports the claim (Casgevy, FDA, CRISPR, first). Strongest cited reporting aligns with the material authorization facts without a named contradiction.

Evidence profile

Key findings

Direct primary evidence supports the claim (Casgevy, FDA, CRISPR, first).

Sources

Analyzed across 2 independent publishers

FDA Approves First Gene Therapies to Treat Patients with ... Fda

High credibility 78/100

government_primaryInstitutional domain

FDA approves CASGEVY, the first CRISPR/Cas9 gene ... - PMC Nih

High credibility 78/100

government_primaryInstitutional domain

Citations

Copy formatted citations from the verified sources above.

Need to verify another claim?

Open Claims Radar to analyze headlines, posts, or links with live source checks.

Verify a claim